- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
First-line FOLFOX therapy for advanced esophageal squamous cell carcinoma: Multicenter prospective study in Japan. (Poster Bd # C18) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_165; Early interventions such as nutritional support and prehabilitation should be studied to improve QOL and OS. Clinical Trial Registration Number 000044485 Sponsored by No funding sources reported Background: Cisplatin (CDDP) plus fluoropyrimidine was the standard first-line treatment in patients with advanced esophageal squamous cell carcinoma (ESCC)...FOLFOX (oxaliplatin 85 mg/m
- |||||||||| Imfinzi (durvalumab) / AstraZeneca
Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1, and cT2N0 esophageal adenocarcinoma with indication for radical surgery: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group (IKF-t057/PRESTO trial). (Poster Bd # N16) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_134; P2 Enrolled pts will receive immunotherapy with durvalumab (1500 mg Q4W) in parallel to 2 cycles FLOT (50 mg/m2 docetaxel, 85 mg/m2 oxaliplatin, 200 mg/m2 calcium folinate and 2600 mg/m2 5FU, Q2W) induction followed by 3 cycles of mFOLFOX (85 mg/m2 oxaliplatin, 200 mg/m2 calcium folinate, 400 mg/m2 5FU bolus and 1600 mg/m2 5FU over 48h, Q2W) plus concomitant radiation (25 daily fractions with 2.0 Gy = ?50Gy)...Currently one patient is recruited. Clinical trial information: NCT05713838.
- |||||||||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204). (Poster Bd # N3) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_121; JCOG2204 is a multi-center, randomized phase II trial comparing neoadjuvant chemotherapy with FLOT (5-fluorouracil/levofolinate/oxaliplatin/docetaxel) versus DOS for resectable type 4 and large type 3 GC...Enrollment in JCOG2204 begun on 14th July, 2023 and clinical trial information is available in Japan Registry of Clinical Trials (jRCTs031230231). Clinical trial information: jRCTs031230231.
- |||||||||| Trial completion, Trial primary completion date: IPLUS: Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6 (clinicaltrials.gov) - Dec 5, 2023
P1/2, N=35, Completed, Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025 Recruiting --> Completed | Trial primary completion date: Dec 2021 --> Aug 2023
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Journal, MSi-H Biomarker, PD(L)-1 Biomarker: A Case of Transverse Colon Cancer Associated with Lynch Syndrome with Excellent Response to Pembrolizumab (Pubmed Central) - Dec 5, 2023 Modified FOLFOX6(mFOLFOX6)regimen was given as a first line chemotherapy and was followed by pembrolizumab after 1 cycle of the mFOLFOX6, because microsatellite instability(MSI)test of the tumor showed high-frequency MSI...Genetic test identified a MSH2 pathogenic variant leading to the diagnosis of Lynch syndrome. The present case shows the importance of MSI test or IHC-MMR before the treatment of metastatic colorectal cancer.
- |||||||||| oxaliplatin / Generic mfg.
Trial completion date, Trial primary completion date: 2 Versus 6 Hour Oxaliplatin Infusions in Patients with Gastrointestinal Cancers (clinicaltrials.gov) - Dec 5, 2023 P2, N=60, Recruiting, The present case shows the importance of MSI test or IHC-MMR before the treatment of metastatic colorectal cancer. Trial completion date: Mar 2024 --> Nov 2024 | Trial primary completion date: Nov 2023 --> Nov 2024
- |||||||||| ginisortamab (UCB6114) / UCB
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases: ONC001: A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors (clinicaltrials.gov) - Dec 4, 2023 P1/2, N=95, Active, not recruiting, Paricalcitol at 7mcg/kg/week in combination with Nal-iri/ 5-FU/LV is safely tolerated, may increase tumor vascularity and warrants further investigation. Recruiting --> Active, not recruiting | N=250 --> 95 | Trial completion date: Feb 2024 --> May 2024 | Trial primary completion date: Feb 2024 --> May 2024
- |||||||||| Journal: Overview of the New Bioactive Heterocycles as Targeting Topoisomerase Inhibitors Useful Against Colon Cancer. (Pubmed Central) - Dec 1, 2023
Thus, here we will review the main works demonstrating the correlation between the inhibition of different isoforms of topoisomerases and the in vitro cytotoxic activity in colon cancer. The findings revealed that natural compounds, semi-synthetic and synthetic analogs showed potential cytotoxicity against several colon cancer cell lines in vitro and that this activity was often accompanied by the ability to inhibit type I and II topoisomerases, demonstrating that these enzymes can be promising drug targets for the development of new chemotherapeutics against colon cancer.
- |||||||||| Rubraca (rucaparib) / Pharma& Schweiz, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Phase classification, Trial primary completion date, Metastases: Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer (clinicaltrials.gov) - Dec 1, 2023 P1/2, N=18, Active, not recruiting, The findings revealed that natural compounds, semi-synthetic and synthetic analogs showed potential cytotoxicity against several colon cancer cell lines in vitro and that this activity was often accompanied by the ability to inhibit type I and II topoisomerases, demonstrating that these enzymes can be promising drug targets for the development of new chemotherapeutics against colon cancer. Phase classification: P2 --> P1/2 | Trial primary completion date: Jan 2020 --> Feb 2024
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal, Metastases: FOLFIRI Chemotherapy for Patients With Metastatic Urachal Carcinoma. (Pubmed Central) - Nov 30, 2023 Trial primary completion date: Jun 2026 --> Sep 2026 FOLFIRI has modest efficacy and good tolerability for the treatment of metastatic urachal carcinoma.
- |||||||||| Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date, Metastases: Toco-CoR: Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 30, 2023 P2, N=74, Recruiting, FOLFIRI has modest efficacy and good tolerability for the treatment of metastatic urachal carcinoma. Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Oct 2023 --> Oct 2024
- |||||||||| Review, Journal: What We Have Learned About Combining a Ketogenic Diet and Chemoimmunotherapy: a Case Report and Review of Literature. (Pubmed Central) - Nov 29, 2023
The patient was later placed on trifluridine/tipiracil and bevacizumab concurrent with a ketogenic diet...On progression, the patient was transitioned to ipilumimab and nivolumab and continued to adhere to the ketogenic diet...In this report, we reviewed the latest literature about cellular mechanism of the ketogenic diet and the efficacy and relationship with chemotherapy and immunotherapy. We are about to open a ketogenic diet protocol at the Veterans Affairs Central California Health Care System in Fresno.
- |||||||||| onvansertib (PCM-075) / Cardiff Oncology
Enrollment closed, Combination therapy, Metastases: Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Nov 29, 2023 P2, N=43, Active, not recruiting, In particular, folinic acid provides a better curative effect than folic acid. Recruiting --> Active, not recruiting
- |||||||||| Review, Journal, BRCA Biomarker: A Simple Overview of Pancreatic Cancer Treatment for Clinical Oncologists. (Pubmed Central) - Nov 28, 2023
There are limited data for maintenance therapy after first-line treatment, though 5-FU or FOLFIRI after initial FOLFIRINOX, and gemcitabine, after initial gemcitabine/nab-paclitaxel, might be considered. We also dedicate space to special rare conditions, such as PDAC with germline BRCA mutations, pancreatic acinar cell carcinoma and adenosquamous carcinoma of the pancreas, with few clinically relevant remarks.
|